ENGN vs. ARCT, EOLS, BCYC, KIDS, PAHC, PLRX, IRON, MNMD, LAB, and YMAB
Should you be buying enGene stock or one of its competitors? The main competitors of enGene include Arcturus Therapeutics (ARCT), Evolus (EOLS), Bicycle Therapeutics (BCYC), OrthoPediatrics (KIDS), Phibro Animal Health (PAHC), Pliant Therapeutics (PLRX), Disc Medicine (IRON), Mind Medicine (MindMed) (MNMD), Standard BioTools (LAB), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "medical" sector.
enGene (NASDAQ:ENGN) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, community ranking, media sentiment and valuation.
enGene has higher earnings, but lower revenue than Arcturus Therapeutics.
Arcturus Therapeutics received 419 more outperform votes than enGene when rated by MarketBeat users. However, 100.00% of users gave enGene an outperform vote while only 65.34% of users gave Arcturus Therapeutics an outperform vote.
In the previous week, enGene had 28 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 32 mentions for enGene and 4 mentions for Arcturus Therapeutics. enGene's average media sentiment score of 0.01 beat Arcturus Therapeutics' score of -0.14 indicating that enGene is being referred to more favorably in the media.
enGene has a beta of -0.4, meaning that its share price is 140% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.65, meaning that its share price is 165% more volatile than the S&P 500.
enGene presently has a consensus price target of $34.40, indicating a potential upside of 136.91%. Arcturus Therapeutics has a consensus price target of $61.33, indicating a potential upside of 125.41%. Given enGene's higher probable upside, research analysts plainly believe enGene is more favorable than Arcturus Therapeutics.
enGene has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -15.65%. enGene's return on equity of 0.00% beat Arcturus Therapeutics' return on equity.
64.2% of enGene shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 13.7% of enGene shares are held by company insiders. Comparatively, 13.8% of Arcturus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
enGene beats Arcturus Therapeutics on 8 of the 14 factors compared between the two stocks.
Get enGene News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
